From: Proposal of initial and maintenance dosing regimens with linezolid for renal impairment patients
Total | TDM group, n = 56 (47.5%) | Non-TDM group, n = 62 (52.5%) | P-value |
Recovery, n (%) | 38 (67.9) | 35 (56.5) | 0.26 |
Duration of linezolid treatment (days), median (IQR) | 30 (19.5–45) | 12 (9–21.3) | < 0.0001 |
Failure, n (%) | 14 (25.0) | 27 (43.6) | 0.052 |
Failure due to persistence of infection, n (%) | 6 (10.7) | 2 (3.2) | 0.15 |
Failure due to hematological toxicity, n (%) | 10 (17.9) | 18 (29.0) | 0.20 |
Failure due to other toxicity, n (%) | 3 (5.4) | 8 (12.9) | 0.21 |
Thirty-day reinfection, n (%) | 5 (8.9) | 4 (6.5) | 0.73 |
Thrombocytopenia | 32 (66.7) | 16 (33.3) | 0.0007 |
RI group | TDM group, n = 21, (60.0%) | Non-TDM group, n = 14, (40.0%) | P-value |
Recovery, n (%) | 15 (71.4) | 5 (35.7) | 0.080 |
Duration of linezolid treatment (days), median (IQR) | 34 (20–46) | 11.5 (8.8–13.3) | < 0.0001 |
Failure, n (%) | 3 (14.3) | 9 (64.3) | 0.0038 |
Failure due to persistence of infection, n (%) | 1 (4.8) | 0 (0.0) | 1.00 |
Failure due to hematological toxicity, n (%) | 2 (9.5) | 8 (57.1) | 0.0056 |
Failure due to other toxicity, n (%) | 0 (0.0) | 2 (14.3) | 0.15 |
Thirty-day reinfection, n (%) | 3 (14.3) | 1 (7.1) | 0.64 |
Thrombocytopenia | 17 (81.0) | 5 (35.7) | 0.012 |
Non-RI group | TDM group, n = 35 (42.2%) | Non-TDM group, n = 48 (57.8%) | P-value |
Recovery, n (%) | 23 (65.7) | 30 (62.5) | 0.82 |
Duration of linezolid treatment (days), median (IQR) | 29 (19–45) | 13.5 (9–22.8) | < 0.0001 |
Failure, n (%) | 18 (37.5) | 11 (31.4) | 0.64 |
Failure due to persistence of infection, n (%) | 2 (4.2) | 5 (14.3) | 0.13 |
Failure due to hematological toxicity, n (%) | 10 (20.8) | 8 (22.9) | 1.00 |
Failure due to other toxicity, n (%) | 6 (12.5) | 3 (8.6) | 0.73 |
Thirty-day reinfection, n (%) | 3 (6.3) | 2 (5.7) | 1.00 |
Thrombocytopenia | 15 (42.9) | 11 (22.9) | 0.060 |